

Reference: FOI.ICB-2526/439

Subject: Funding Criteria and Weight Loss Drugs

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE
<p>For each of the questions below please provide any relevant policies and information, including how long the policy has been in place and/or if a policy is being planned, considered, or is potentially changing in the future:</p>	
<p>1. Do you either routinely fund, or provide criteria-based access to funding for, weight-loss medications such as (for example semaglutide, tirzepatide) when used specifically for weight management/obesity?</p>	<p>GLP-1 receptor agonists or dual GIP/GLP-1 agonists are routinely funded according to NICE technology appraisal recommendations as detailed and the NHS England funding variation for tirzepatide in primary care. Further information can be found on the BNSSG Remedy website:</p> <p>6.3 Diabetes mellitus and hypoglycaemia (Remedy BNSSG ICB)</p> <p>Weight Management - Tirzepatide (Mounjaro) (Remedy BNSSG ICB)</p> <p>There is no commissioning policy for these medications as criteria-based access.</p>

<p>2. If you do provide criteria-based access, please provide details of the criteria (for example BMI thresholds, presence of weight-related comorbidities, requirement for participation in a structured weight-management programme), or tell me where this information can be found.</p>	<p>Not applicable</p>
<p>3. If you provide either criteria-based access or routine funding, is this only for patients with obesity and comorbidities, or is access provided more widely (for example overweight with high-risk features)?</p>	<p>Routine funding for patients with obesity and related co-morbidities follows the NICE Technology Appraisal Guidance for these medicines and the NHS England Interim Commissioning Guidance for Tirzepatide.</p> <p>Further information can be found on the BNSSG Remedy website: 6.3 Diabetes mellitus and hypoglycaemia (Remedy BNSSG ICB) Weight Management - Tirzepatide (Mounjaro) (Remedy BNSSG ICB)</p>
<p>4. If you provide criteria-based funding, is any form of prior approval or Individual Funding Request (IFR) required before initiating treatment?</p>	<p>Not applicable</p>
<p>5. How long has the current policy on pharmacological weight-loss treatment been in place, and are there any planned or pending changes to this policy (for example in response to new national guidance on specific drugs such as tirzepatide)?</p>	<p>Not applicable</p>

The information provided in this response is accurate as of 12 March 2026 and has been approved for release by Dr Geeta Iyer, Deputy Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.